AU2022373753A1 - Treatment of irritability in subjects with autism spectrum disorders with moderate to severe anxiety and/or social avoidance - Google Patents
Treatment of irritability in subjects with autism spectrum disorders with moderate to severe anxiety and/or social avoidance Download PDFInfo
- Publication number
- AU2022373753A1 AU2022373753A1 AU2022373753A AU2022373753A AU2022373753A1 AU 2022373753 A1 AU2022373753 A1 AU 2022373753A1 AU 2022373753 A AU2022373753 A AU 2022373753A AU 2022373753 A AU2022373753 A AU 2022373753A AU 2022373753 A1 AU2022373753 A1 AU 2022373753A1
- Authority
- AU
- Australia
- Prior art keywords
- cbd
- asd
- subject
- irritability
- abc
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/658—Medicinal preparations containing organic active ingredients o-phenolic cannabinoids, e.g. cannabidiol, cannabigerolic acid, cannabichromene or tetrahydrocannabinol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0014—Skin, i.e. galenical aspects of topical compositions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/06—Ointments; Bases therefor; Other semi-solid forms, e.g. creams, sticks, gels
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Dermatology (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202163271015P | 2021-10-22 | 2021-10-22 | |
| US63/271,015 | 2021-10-22 | ||
| PCT/US2022/078449 WO2023070045A1 (en) | 2021-10-22 | 2022-10-20 | Treatment of irritability in subjects with autism spectrum disorders with moderate to severe anxiety and/or social avoidance |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AU2022373753A1 true AU2022373753A1 (en) | 2024-05-09 |
Family
ID=84358575
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| AU2022373753A Pending AU2022373753A1 (en) | 2021-10-22 | 2022-10-20 | Treatment of irritability in subjects with autism spectrum disorders with moderate to severe anxiety and/or social avoidance |
Country Status (10)
| Country | Link |
|---|---|
| US (1) | US20240342198A1 (https=) |
| EP (1) | EP4419091A1 (https=) |
| JP (1) | JP2024536581A (https=) |
| KR (1) | KR20240093852A (https=) |
| CN (1) | CN118284412A (https=) |
| AU (1) | AU2022373753A1 (https=) |
| CA (1) | CA3235677A1 (https=) |
| IL (1) | IL312328A (https=) |
| MX (1) | MX2024004766A (https=) |
| WO (1) | WO2023070045A1 (https=) |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA3300266A1 (en) | 2017-09-28 | 2026-03-02 | Harmony Biosciences Management, Inc. | Treatment of fragile x syndrome with cannabidiol |
| US12582664B2 (en) | 2017-09-28 | 2026-03-24 | Harmony Biosciences Management, Inc. | Treatment of fragile x syndrome with cannabidiol |
Family Cites Families (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US8449908B2 (en) | 2000-12-22 | 2013-05-28 | Alltranz, Llc | Transdermal delivery of cannabidiol |
| CA2760460C (en) | 2009-04-28 | 2019-04-02 | Alltranz Inc. | Transdermal formulations of cannabidiol comprising a penetration enhancer and methods of using the same |
| CA3300266A1 (en) * | 2017-09-28 | 2026-03-02 | Harmony Biosciences Management, Inc. | Treatment of fragile x syndrome with cannabidiol |
| WO2019224824A1 (en) * | 2018-05-24 | 2019-11-28 | To Pharmaceuticals Llc | Cannabis-based compositions for the treatment of autistic spectrum disorders |
| US20210369643A1 (en) * | 2020-05-26 | 2021-12-02 | Zynerba Pharmaceuticals, Inc. | Treatment of fragile x syndrome and autism spectrum disorder with cannabidiol |
| BR112022026044A2 (pt) * | 2020-06-29 | 2023-03-07 | Zynerba Pharmaceuticals Inc | Tratamento de síndrome do x frágil com canabidiol |
| WO2022103639A1 (en) * | 2020-11-16 | 2022-05-19 | Orcosa Inc. | Methods of treating autoimmune or inflammatory conditions with cannabidiol or its derivatives/analogs |
-
2022
- 2022-10-20 CN CN202280077354.9A patent/CN118284412A/zh active Pending
- 2022-10-20 CA CA3235677A patent/CA3235677A1/en active Pending
- 2022-10-20 IL IL312328A patent/IL312328A/en unknown
- 2022-10-20 WO PCT/US2022/078449 patent/WO2023070045A1/en not_active Ceased
- 2022-10-20 EP EP22803457.5A patent/EP4419091A1/en active Pending
- 2022-10-20 JP JP2024523674A patent/JP2024536581A/ja active Pending
- 2022-10-20 MX MX2024004766A patent/MX2024004766A/es unknown
- 2022-10-20 KR KR1020247016925A patent/KR20240093852A/ko active Pending
- 2022-10-20 AU AU2022373753A patent/AU2022373753A1/en active Pending
-
2024
- 2024-04-22 US US18/642,059 patent/US20240342198A1/en active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| JP2024536581A (ja) | 2024-10-04 |
| CN118284412A (zh) | 2024-07-02 |
| EP4419091A1 (en) | 2024-08-28 |
| IL312328A (en) | 2024-06-01 |
| WO2023070045A1 (en) | 2023-04-27 |
| KR20240093852A (ko) | 2024-06-24 |
| US20240342198A1 (en) | 2024-10-17 |
| CA3235677A1 (en) | 2023-04-27 |
| MX2024004766A (es) | 2024-06-11 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US12226373B2 (en) | Treatment of fragile X syndrome with cannabidiol | |
| US20240342198A1 (en) | Treatment of irritability in subjects with autism spectrum disorders with moderate to severe anxiety and/or social avoidance | |
| US12582664B2 (en) | Treatment of fragile x syndrome with cannabidiol | |
| US20250288539A1 (en) | Treatment of fragile x syndrome and autism spectrum disorder with cannabidiol | |
| US20260027137A1 (en) | Treatment of fragile x syndrome with cannabidiol | |
| US20250177322A1 (en) | Treatment of fragile x syndrome with cannabidiol |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| HB | Alteration of name in register |
Owner name: HARMONY BIOSCIENCES MANAGEMENT, INC. Free format text: FORMER NAME(S): ZYNERBA PHARMACEUTICALS, INC. |